Patents by Inventor Inder Bhamra

Inder Bhamra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20230365549
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: April 3, 2023
    Publication date: November 16, 2023
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
    Patent number: 11643408
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 9, 2023
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20230121489
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: August 29, 2022
    Publication date: April 20, 2023
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
    Patent number: 11459326
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: October 4, 2022
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20210046076
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: September 1, 2020
    Publication date: February 18, 2021
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20200407356
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 31, 2020
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
    Patent number: 10793562
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 6, 2020
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway
    Patent number: 10793560
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: RedX Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20190144447
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 16, 2019
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors
    Patent number: 10202375
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: February 12, 2019
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20180319788
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway
    Patent number: 10047079
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: August 14, 2018
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS
    Publication number: 20170298062
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 19, 2017
    Inventors: Inder Bhamra, Michael Mathieson, Craig Donoghue, Richard Testar
  • N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY
    Publication number: 20170275276
    Abstract: Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Application
    Filed: October 8, 2015
    Publication date: September 28, 2017
    Applicant: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • Heterocyclic compounds as hedgehog signaling pathway inhibitors
    Patent number: 9579319
    Abstract: This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: February 28, 2017
    Assignee: Redx Pharma PLC
    Inventors: Richard Armer, Matilda Bingham, Inder Bhamra, Andrew McCarroll
  • HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS
    Publication number: 20160113928
    Abstract: This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 28, 2016
    Inventors: Richard Armer, Matilda Bingham, Inder Bhamra, Andrew McCarroll
  • Rosuvastatin and atorvastatin derivatives
    Patent number: 9006282
    Abstract: This invention relates to the discovery of novel rosuvastatin and atorvastatin analogues.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: April 14, 2015
    Assignee: Redx Pharma Limited
    Inventors: Derek Lindsay, Peter Jackson, Stephen Hindley, Inder Bhamra
  • Rosuvastatin and Atorvastatin Derivatives
    Publication number: 20130303773
    Abstract: This invention relates to the discovery of novel rosuvastatin and atorvastatin analogues.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Derek Lindsay, Peter Jackson, Stephen Hindley, Inder Bhamra
  • Rosuvastatin and atorvastatin derivatives
    Patent number: 8513412
    Abstract: This invention relates to the discovery of novel rosuvastatin and atorvastatin analogues.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: August 20, 2013
    Assignee: RedX Pharna Limited
    Inventors: Derek Lindsay, Peter Jackson, Stephen Hindley, Inder Bhamra
  • Rosuvastatin and Atorvastatin Derivatives
    Publication number: 20110319617
    Abstract: This invention relates to the discovery of novel rosuvastatin and atorvastatin analogues.
    Type: Application
    Filed: March 10, 2010
    Publication date: December 29, 2011
    Applicant: Bradford Pharma Limited
    Inventors: Derek Lindsay, Peter Jackson, Stephen Hindley, Inder Bhamra